| 廖春壮,覃学勇,黄茜,黄坚,甘航.托法替布联合阿达木单抗序贯治疗中轴型脊柱关节炎患者疗效分析.[J].中南医学科学杂志.,2024,(6):992-994, 1024. |
| 托法替布联合阿达木单抗序贯治疗中轴型脊柱关节炎患者疗效分析 |
| Efficacy analysis of sequential treatment of axial spondyloarthritis patients with tofacitinib combined with adalimumab |
| 投稿时间：2023-07-20 修订日期：2024-05-30 |
| DOI：10.15972/j.cnki.43-1509/r.2024.06.029 |
| 中文关键词: 托法替布 阿达木单抗 序贯治疗 中轴型脊柱关节炎 |
| 英文关键词:tofacitinib adalimumab sequential treatment axial spondyloarthritis |
| 基金项目:广西壮族自治区卫生健康委员会科研课题(Z-B20221540) 作者简介:廖春壮,硕士,副主任医师,研究方向为炎性关节痛治疗,E-mail为watf20230606@163.com。 |
|
| 摘要点击次数: 38 |
| 全文下载次数: 27 |
| 中文摘要: |
| 目的分析托法替布联合阿达木单抗序贯治疗中轴型脊柱关节炎患者的疗效。 方法选取中轴型脊柱关节炎患者80例,随机均分为对照组(阿达木单抗治疗)和观察组(阿达木单抗联合托法替布序贯治疗)。比较两组治疗后疗效,包括Bath强直性脊柱炎功能指数(BASFI)评分、强直性脊柱炎疾病活动评分(ASDAS)、ASAS健康指数(ASAS HI)评分、红细胞沉降率(ESR)、C反应蛋白(CRP)和不良反应情况。 结果与治疗前比较,两组治疗后ASDAS评分、BASFI评分、ASAS HI评分、ESR、CRP水平均降低,EQ5D-5L健康效应值升高；且治疗后观察组较对照组更为显著(P＜0.05)。观察组不良反应发生率少于对照组(P＜0.05)。结论托法替布联合阿达木单抗序贯治疗中轴型脊柱关节炎患者疗效更好,安全性较高,值得临床推广应用。 |
| 英文摘要: |
| AimTo analyze the efficacy of sequential treatment of axial spondyloarthritis patients with tofacitinib combined with adalimumab. MethodsEighty patients with axial spondyloarthritis were selected and randomly divided into a control group (treated with adalimumab) and an observation group (treated with adalimumab combined with tofacitinib sequentially). The efficacy of two treatment groups, including Bath ankylosing spondylitis functional index (BASFI), ankylosing spondylitis disease activity score (ASDAS), ASAS health index (ASAS HI) score, erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), and adverse reactions, were compared. ResultsCompared with the situations before treatment, both groups showed a decrease in ASDAS score, BASFI, ASAS HI score, ESR, and CRP levels after treatment, while the EQ5D-5L health effect value increased; and after treatment, these changes in observation group were more significant than the control group (P＜0.05). The incidence of adverse reactions in the observation group was lower than that in the control group (P＜0.05). ConclusionThe sequential treatment of axial spondyloarthritis patients with tofacitinib combined with adalimumab has better efficacy and higher safety, which is worthy of clinical promotion and application. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|